We’re excited to welcome the 2019 American Academy of Dermatology (AAD) meeting to Washington, D.C. this week. As AAD comes to town, we wanted to offer a few recommendations from our D.C. staff. UCB’s D.C. office focuses on public policy with colleagues in advocacy, policy, public affairs, and regulatory.

For International Rare Disease Day, our Global Head of the Rozimab Mission, Chris Clark, shares insights about how UCB is leveraging and growing our capabilities to deliver value for specific patient populations new to UCB. Read the full article on LinkedIn.

With Innovation Day upcoming on February 17, we’re highlighting our approach to innovation, what we call at UCB the “patient-science-solution” model. Everything we do starts and ends with what patients value, but it is a continuous journey. Starting with the patient – we listen to their experiences, what they value, their needs, and keep them at the heart of everything we do.